Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simvastatin: a review.

Terje R Pedersen1, Jonathan A Tobert

  • 1Centre for Preventive Medicine, Ullevål University Hospital, Oslo, Norway. t.r.pedersen@ioks.uio.no

Expert Opinion on Pharmacotherapy
|December 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol.

The Journal of clinical endocrinology and metabolism·2022
Same author

LDL Cholesterol-How Low Can We Go?

Endocrinology and metabolism clinics of North America·2022
Same author

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial.

European journal of preventive cardiology·2021
Same author

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.

Circulation journal : official journal of the Japanese Circulation Society·2021
Same author

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.

Atherosclerosis. Supplements·2021
Same author

LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.

Atherosclerosis·2021
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Simvastatin, a cholesterol-lowering drug, significantly reduces cardiovascular risk and mortality. It effectively lowers LDL cholesterol with a good safety profile, even available over-the-counter in the UK.

Area of Science:

  • Cardiovascular Pharmacology
  • Lipid Metabolism
  • Pharmacotherapy

Background:

  • Simvastatin is a widely used HMG-CoA reductase inhibitor for cholesterol management.
  • It effectively reduces LDL-C, triglycerides, and apolipoprotein B.
  • Potential rare adverse effects include myopathy and rhabdomyolysis.

Purpose of the Study:

  • To review the efficacy and safety of simvastatin in cardiovascular risk reduction.
  • To highlight findings from major outcome trials like 4S and HPS.
  • To discuss the drug's current availability and new formulations.

Main Methods:

  • Analysis of data from large-scale clinical trials (Scandinavian Simvastatin Survival Study, Heart Protection Study).
  • Review of simvastatin's pharmacokinetic and pharmacodynamic properties.

Related Experiment Videos

  • Examination of adverse event profiles and drug interactions.

    • Main Results:

    • Simvastatin demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C) by 47% at 80 mg/day.
    • Major trials showed substantial benefits in cardiovascular outcomes and a reduction in all-cause mortality.
    • Beneficial effects were observed across diverse patient populations, including those with diabetes and below-average LDL-C levels.

    Conclusions:

    • Simvastatin is a proven effective agent for reducing cardiovascular risk and mortality.
    • Its established safety record and efficacy support its continued use.
    • Recent availability as a combination product and over-the-counter option expands accessibility.